Complement Antagonist Induced Treg Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate T cell responses, leading to uncontrolled lymphoproliferation and autoimmune disorders, as they lack efficient mechanisms to terminate T cell activation and induce regulatory T cells.
Innovation Solution
Administering complement antagonists to inhibit C3aR and C5aR signal transduction in CD4+ T cells, promoting TGF-β expression and differentiation into FoxP3+ Treg cells, which can then be used to treat T cell-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to regulate T cell responses, then T cell activation control is insufficient, but current methods lack efficient mechanisms to terminate T cell activation and induce regulatory T cells
Solution Approach 1:
The patent introduces complement antagonists (specifically C3aR and C5aR antagonists) as intermediary substances that mediate between the immune system components. These antagonists block the complement receptor signaling pathway, thereby inducing Treg cell differentiation and improving T cell activation control without requiring complex engineered systems
Solution Approach 2:
The patent changes the biochemical parameter of complement receptor signaling by introducing antagonists that specifically inhibit C3aR and C5aR pathways. This parameter change (blocking complement signaling) shifts the T cell differentiation pathway toward Treg cell formation, providing a controlled mechanism to terminate T cell activation
2Productivity
If C3aR and C5aR signaling is inhibited to induce Treg cells, then regulatory T cell differentiation is enhanced, but the mechanism requires specific complement antagonist administration
Solution Approach 1:
The patent leverages the body's own complement system components (C3aR and C5aR receptors) as the target for induction. By using complement antagonists that block these endogenous receptors, the method achieves Treg cell differentiation through self-regulation of the immune system's existing pathways, eliminating the need for external complex manufacturing or delivery systems
Data Source
AI summary
A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-β1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.